Italian pharmaceutical company Recordati Korean corporation was launched. Recordati Korea (Representative Lee Yeon-jae in Asia) announced on the 27th that it will officially launch its Korean branch and Asia-Pacific regional headquarters. The company is an Italian pharmaceutical company with a history of more than 90 years. Accordingly, the corporate name of the existing EUSA Pharma Korea will be changed.

Recordati will be in charge of marketing Sylvant, a treatment for multicentric Castleman's disease (MCD), and Carbaglu, a treatment for hyperammonemia, and is preparing a wide portfolio for rare diseases such as Neuroblastoma and Cushing's syndrome. Lee Yeon-jae, CEO of Asia, said, "Recordati has expa